• FLAG tag Peptide for Kinesin Assay Workflows

  2026-08-19

  The FLAG tag Peptide (DYKDDDDK) enables gentle affinity purification, rapid recombinant protein detection, and controlled preparation of motor–adaptor complexes. Its value is especially clear in BicD–MAP7–kinesin reconstitution, where matched protein quality and tag-aware assay design help separate binding, recruitment, and processive movement.

• JC-1 Mitochondrial Membrane Potential Assay Kit Guide

  2026-08-19

  Use the JC-1 Mitochondrial Membrane Potential Assay Kit to convert mitochondrial depolarization into a practical red-to-green fluorescence measurement for cancer pharmacology, apoptosis assay design, and mitochondrial function analysis. Its ratiometric format and CCCP control help distinguish genuine ΔΨm changes from simple differences in cell number or fluorescence intensity.

• Psoralen-Induced Cholestasis via ERK1/2

  2026-08-18

  The reference study shows that psoralen and isopsoralen, estrogen-like constituents of Psoraleae Fructus, produce cholestatic liver injury in zebrafish larvae through estrogen-associated ERK1/2 activation. By combining estrogenicity assays, bile-flow measurements, gene-expression analysis, and pharmacological rescue, the work identifies ERK1/2 as a mechanistically relevant target rather than merely a correlated signaling marker.

• Proteoform-Specific Drug Interactions in Native Membranes

  2026-08-18

  The reference study introduces native top-down mass spectrometry for defining how individual membrane-protein proteoforms interact with ligands in intact lipid environments. Using retinal rod disc membranes, the authors resolved rhodopsin and G-protein modifications and showed that Vardenafil and sildenafil display differential interactions with retinal PDE6, highlighting a route toward more precise off-target and proteoform analysis.

• Calpain Inhibitor I, ALLN: Practical Lab Guide

  2026-08-17

  Calpain Inhibitor I, ALLN (SKU A2602) provides a research tool for probing calpain- and cathepsin-associated proteolysis in apoptosis assays, inflammation research, and ischemia-reperfusion injury models. It is water-insoluble, requires solvent-controlled preparation, and should not be treated as a diagnostic, therapeutic, or exclusively calpain-specific reagent.

• RHEB Neddylation Activates mTORC1 in Liver Cancer

  2026-08-17

  The reference study identifies RHEB as a non-cullin substrate of the UBE2F-SAG neddylation machinery and maps lysine 169 as a functionally important modification site. Its cell and liver-specific genetic models connect RHEB neddylation with lysosomal localization, mTORC1 activation, steatosis, and liver tumorigenesis, while also defining experimental routes for studying this signaling axis.

• Nanoparticle mRNA Delivery Reverses Trastuzumab Resistance

  2026-08-16

  Dong and colleagues developed a tumor-microenvironment pH-responsive nanoparticle for systemic PTEN mRNA delivery in trastuzumab-resistant breast cancer. The study links nanoparticle-triggered tumor uptake and intracellular PTEN restoration to PI3K/Akt pathway inhibition, providing a mechanistic strategy for resensitizing resistant tumors rather than intensifying HER2 blockade alone.

• Psoralen, ERK1/2, and Cholestatic Injury

  2026-08-15

  The 2024 reference study shows that psoralen and isopsoralen, estrogen-like constituents of Psoraleae Fructus, produce cholestatic liver injury in zebrafish larvae through coordinated estrogen-associated changes and ERK1/2 activation. Its combination of estrogenic biomarkers, bile-flow phenotyping, bile-acid gene analysis, and pharmacological rescue identifies ERK1/2 as a testable mechanistic node, while also defining the limits of translating zebrafish findings to human or oncology models.

• Formononetin Protects Against Oxaliplatin Neurotoxicity

  2026-08-14

  The reference study identifies formononetin as a potential neuroprotective isoflavone that limits oxaliplatin-induced oxidative stress and neuronal apoptosis through the Nrf2/HO-1 pathway. Its central advance is the preservation of oxaliplatin and paclitaxel anticancer activity in tumor-cell models, although protection was weaker against paclitaxel-associated neurite damage.

• SB743921: From Mitotic Arrest to Translational Insight

  2026-08-14

  SB743921 is a selective kinesin spindle protein inhibitor that connects a defined mitotic mechanism with a more rigorous framework for measuring cancer drug responses. By separating mitotic arrest, growth inhibition, and cell death, translational researchers can extract more value from in vitro and tumor xenograft models.

• 2-NBDG Glucose Uptake Assay Kit for HCC

  2026-08-13

  Measure transporter-dependent glucose uptake without radioactivity, while using PI and phloretin controls to strengthen interpretation. The 2-NBDG Glucose Uptake Assay Kit is especially useful for connecting metabolic phenotypes with sorafenib response, ferroptosis, and disease-relevant cell models.

• DRD4, Akt/β-Catenin, and Liver Cancer Resistance

  2026-08-13

  The 2024 British Journal of Cancer study identifies DRD4 as a regulator of liver cancer stem cell-like behavior, chemotherapy resistance, and tumorigenicity through the PI3K/Akt/GSK-3β/β-catenin axis. Its integrated expression, patient-association, perturbation, and localization analyses suggest that DRD4-linked signaling may be a tractable vulnerability, while downstream pathway experiments can help distinguish stemness effects from general cytotoxicity.

• Pyridostatin: A Translational G-Quadruplex Strategy

  2026-08-12

  Pyridostatin TFA offers a practical way to connect G-quadruplex stabilization with telomere dysfunction, cancer-cell phenotypes, and more rigorous translational assay design. This thought-leadership framework also explains how recent RNA G-quadruplex findings in TDP-43 biology broaden the research question without overstating the evidence.

• GDC-0994: Selective ERK1/2 Inhibitor Guide

  2026-08-12

  GDC-0994 is a potent, selective ERK1/2 inhibitor for research on MAP kinase signaling, oncogenic RAS/BRAF models, and ERK-dependent tumor cell proliferation. Product data report nanomolar biochemical potency, oral bioavailability, and preclinical activity in KRAS-mutant and BRAF-mutant xenograft models.

• HyperPFU™ high-fidelity DNA polymerase: PCR Guide

  2026-08-11

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, and otherwise difficult DNA templates where conventional PCR enzymes may underperform. Its proofreading activity produces blunt-ended products, so it should not be selected for workflows that require 3′-A overhangs or sticky-end PCR products.

8187 records 4/546 page Previous Next 12345 下5页 Last page